News 2023-09-28
The Pharma Crystallization Summit (PCS) is held annually to bring together developers of new medicines with crystallization challenges and the crystallization experts (solution providers) in the industry and academia.
The Pharma Crystallization Summit (PCS) is held annually to bring together developers of new medicines with crystallization challenges and the crystallization experts (solution providers) in the industry and academia. PCS programs are designed to stimulate in-depth discussions on common and/or leading bottleneck issues related to crystallization of drug substance (DS) as well as the intermediates, the technologies and solutions that are available or underdevelopment. The discussions help new medicine developers to make educated and phase-appropriate decisions, and crystallization experts to understand better the critical needs for providing effective solutions.
The Pharma Crystallization Summit (PCS) has been serving effectively for bridging the gap between drug substance (DS) and drug product (DP) developments. PCS 2023 will be held on October 5 – 6 at New Jersey Institute of Technology (NJIT), Newark, NJ, USA. Extending from the valued topics in the past, this 4th PCS will focus on the following topics:
Session I: Enabling Greener DS Synthetics Routes
Session II: Enabling Desired DS Quality Attributes
Session III: Enabling Improved DP Performance
Panel Discussion Topics:
1) Crystallization challenges and dream solutions supporting synthetic route optimization
2) API isolation challenges and better solutions to ensure robust production
3) Addressing formulation challenges via particle engineering and co-processing
End of Summit & See you in 2024!
Others
More
News 2024-10-31
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
Recently, Porton Pharma has achieved a significant capacity breakthrough at its GMP manufacturing facility in Fengxian, Shanghai, China, further enhancing its production capabilities and technological strength in new modality areas such as peptide and oligonucleotide drugs. This upgrade represents an important step in Porton's commitment to becoming a leading global CDMO company.
News 2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
On October 24, 2024, Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.
